Luteolin offers novel therapeutic regimen in rotenone-induced Parkinson disease via modulation of TNF-α/FXMRP/serotonin/tyrosine hydroxylase signaling pathway. NJPS [网际网络]. 2025年12月31日 [见引于 2026年4月14日];40(2):251-62. 载于: https://www.ojshostng.com/index.php/njphysiologicalsciences/article/view/4001